Allergie à l’insuline humaine recombinante : à propos de 3 cas avec manifestations immédiates généralisées

Imiela, Astrid; Tavernier, J.; Carrotte-Lefebvre, I.; Devemy, F.; Delaporte, E.; Lamblin, C

doi:10.1016/s0335-7457(03)00045-5

Cited by 2 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This allergy was confirmed by intradermo-reaction tests for all kinds of insulin, except lispro. A treatment with CSII and insulin lispro was initiated and continued with a good tolerance and a good metabolic control [72]. In an 81-year-old type 2 diabetic patient, hypersensitivity to insulin was described consisting of local skin reaction followed by general urticarian lesions.…”

Section: Csii With Insulin Analogues and Insulin Allergymentioning

confidence: 99%

Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues

Radermecker

Scheen

2007

Diabetes Metabolism Res

113

View full text Add to dashboard Cite

SUMMARYThe purification of animal insulin preparations and the use of human recombinant insulin have markedly reduced the incidence but not completely suppressed the occurrence of insulin allergy manifestations. Advances in technologies concerning the mode of delivery of insulin, i.e. continuous subcutaneous insulin infusion (CSII), and the use of insulin analogues, resulting from the alteration in the amino acid sequence of the native insulin molecule, may influence the immunogenicity and antigenicity of native insulin. Instead of increasing allergy reactions, CSII has been reported to represent a successful alternative treatment in diabetic patients presenting local or generalized allergy to insulin or other components (zinc, protamine) of conventional treatment. Most recent reports concern CSII-treated patients using short-acting insulin analogues (essentially insulin lispro), although the precise role of these insulin analogues remains unclear as allergy to 1 them has also been described. Finally, data on antigenicity and immunogenicity of long-acting insulin analogues (glargine, detemir), which may mimic the basal insulin delivery with CSII, remain scarce at present time.

show abstract

Section: Csii With Insulin Analogues and Insulin Allergymentioning

confidence: 99%